Peri-operative corticosteroid supplementation guideline adherence

IF 7.5 1区 医学 Q1 ANESTHESIOLOGY
Anaesthesia Pub Date : 2025-01-30 DOI:10.1111/anae.16556
Lynn A. Miggelbrink, Marije Marsman, Juul van de Wetering, Wilton A. van Klei, Teus H. Kappen
{"title":"Peri-operative corticosteroid supplementation guideline adherence","authors":"Lynn A. Miggelbrink,&nbsp;Marije Marsman,&nbsp;Juul van de Wetering,&nbsp;Wilton A. van Klei,&nbsp;Teus H. Kappen","doi":"10.1111/anae.16556","DOIUrl":null,"url":null,"abstract":"<p>Corticosteroids are prescribed commonly to patients with autoimmune or pulmonary diseases, post-transplant and neurosurgery, as well as to patients with adrenal insufficiency [<span>1, 2</span>]. These patients are at risk of tertiary adrenal gland insufficiency, for which supplementation of corticosteroids during stress, such as surgery, is advised [<span>3, 4</span>]. The Peri-operative Replacement of Exogenous Steroids (PREdS) study performed an audit of compliance to guidelines for supplemental corticosteroids in patients with possible adrenal insufficiency in the UK [<span>5</span>]. A total of 21,411 adult patients undergoing surgery under the care of an anaesthetist were screened, of whom 277 (1.3%) used corticosteroids (i.e. they were considered at risk of tertiary adrenal gland insufficiency). Peri-operative prescription of supplementation was fully compliant in only 9% of the patients and 14% received none.</p><p>In a retrospective cohort study, we investigated guideline adherence for such patients in our academic centre. The local clinical guideline is based on a Dutch nationwide guideline, comparable with the one used in the UK (Table 1). Patients are deemed at risk if they are using prednisolone ≥ 7.5 mg or equivalent. Supplementation dosage depends on surgical risk, so we documented compliance based on a patient's surgical procedure risk.</p><p>A total of 15,246 patients undergoing elective non-cardiac surgery under general or spinal anaesthesia between January 2017 and June 2018 were included, of whom 390 were at risk of tertiary adrenal gland-insufficiency. Patients had a median (IQR [range]) age of 56 (45–69 [18–85]) y, 178 (45%) were female and 107 (27%) were scheduled for neurosurgery. On the day of surgery, 32 of 390 patients (8%) received hydrocortisone supplementation in accordance with the guidelines and 188 (48%) received another corticosteroid for an alternative reason, for example, dexamethasone for postoperative nausea or for neurosurgery. None of the remaining 170 (44%) patients received supplementation.</p><p>Of the 147 patients (38%) undergoing low-risk surgery, 26 (18%) received supplementation according to the guidelines, while 38 (36%) received corticosteroids for other reasons, of whom 36 (95%) received an adequate equivalent dose. Of the 243 patients (62%) undergoing intermediate/high-risk surgery, 6 (2%) received supplemental corticosteroids according to the guidelines and 150 (62%) received corticosteroids for other reasons. Of these 150 patients, 27 (18%) received an adequate equivalent dose. On the first postoperative day, peri-operative prescription of supplementation was fully compliant in 10 (4%) of the 243 intermediate/high-risk patients.</p><p>In conclusion, our hospital recorded an 8% compliance rate with the guidelines for prescribing peri-operative corticosteroid supplementation, similar to the 9% compliance rate found in the PREDs study [<span>5</span>]. Our study predates the Association of Anaesthetists' guidelines, yet the results indicate that peri-operative corticosteroid supplementation for chronic users remains controversial [<span>4</span>]. Despite over 60 years of recommendations, these guidelines are based on sparse, low-quality evidence and need further scrutiny.</p>","PeriodicalId":7742,"journal":{"name":"Anaesthesia","volume":"80 4","pages":"454-455"},"PeriodicalIF":7.5000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/anae.16556","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaesthesia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/anae.16556","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Corticosteroids are prescribed commonly to patients with autoimmune or pulmonary diseases, post-transplant and neurosurgery, as well as to patients with adrenal insufficiency [1, 2]. These patients are at risk of tertiary adrenal gland insufficiency, for which supplementation of corticosteroids during stress, such as surgery, is advised [3, 4]. The Peri-operative Replacement of Exogenous Steroids (PREdS) study performed an audit of compliance to guidelines for supplemental corticosteroids in patients with possible adrenal insufficiency in the UK [5]. A total of 21,411 adult patients undergoing surgery under the care of an anaesthetist were screened, of whom 277 (1.3%) used corticosteroids (i.e. they were considered at risk of tertiary adrenal gland insufficiency). Peri-operative prescription of supplementation was fully compliant in only 9% of the patients and 14% received none.

In a retrospective cohort study, we investigated guideline adherence for such patients in our academic centre. The local clinical guideline is based on a Dutch nationwide guideline, comparable with the one used in the UK (Table 1). Patients are deemed at risk if they are using prednisolone ≥ 7.5 mg or equivalent. Supplementation dosage depends on surgical risk, so we documented compliance based on a patient's surgical procedure risk.

A total of 15,246 patients undergoing elective non-cardiac surgery under general or spinal anaesthesia between January 2017 and June 2018 were included, of whom 390 were at risk of tertiary adrenal gland-insufficiency. Patients had a median (IQR [range]) age of 56 (45–69 [18–85]) y, 178 (45%) were female and 107 (27%) were scheduled for neurosurgery. On the day of surgery, 32 of 390 patients (8%) received hydrocortisone supplementation in accordance with the guidelines and 188 (48%) received another corticosteroid for an alternative reason, for example, dexamethasone for postoperative nausea or for neurosurgery. None of the remaining 170 (44%) patients received supplementation.

Of the 147 patients (38%) undergoing low-risk surgery, 26 (18%) received supplementation according to the guidelines, while 38 (36%) received corticosteroids for other reasons, of whom 36 (95%) received an adequate equivalent dose. Of the 243 patients (62%) undergoing intermediate/high-risk surgery, 6 (2%) received supplemental corticosteroids according to the guidelines and 150 (62%) received corticosteroids for other reasons. Of these 150 patients, 27 (18%) received an adequate equivalent dose. On the first postoperative day, peri-operative prescription of supplementation was fully compliant in 10 (4%) of the 243 intermediate/high-risk patients.

In conclusion, our hospital recorded an 8% compliance rate with the guidelines for prescribing peri-operative corticosteroid supplementation, similar to the 9% compliance rate found in the PREDs study [5]. Our study predates the Association of Anaesthetists' guidelines, yet the results indicate that peri-operative corticosteroid supplementation for chronic users remains controversial [4]. Despite over 60 years of recommendations, these guidelines are based on sparse, low-quality evidence and need further scrutiny.

围手术期皮质类固醇补充指南依从性
皮质类固醇通常用于自身免疫性或肺部疾病、移植后和神经外科手术以及肾上腺功能不全患者[1,2]。这些患者有三级肾上腺功能不全的风险,因此建议在手术等应激过程中补充皮质类固醇[3,4]。围手术期外源性类固醇替代(PREdS)研究对英国bbb可能存在肾上腺功能不全的患者补充皮质类固醇指南的依从性进行了审核。总共筛选了21,411名在麻醉师护理下接受手术的成年患者,其中277名(1.3%)使用皮质类固醇(即他们被认为有三级肾上腺功能不全的风险)。只有9%的患者在围手术期完全依从补充处方,14%的患者没有服用。在一项回顾性队列研究中,我们调查了我们学术中心此类患者的指南依从性。当地临床指南基于荷兰全国指南,与英国使用的指南相当(表1)。如果患者使用泼尼松龙≥7.5 mg或同等剂量,则认为存在风险。补充剂量取决于手术风险,因此我们根据患者手术风险记录了依从性。表1。皮质类固醇补充指南。类型的手术* Pre-operativePostoperativeDay surgeryDay 1天2天3 low-risk100 mg氢化可的松surgeryn前静脉输液或坜1 h / / / aIntermediate high-risk100 mg氢化可的松surgery3前静脉输液或坜1 h×40毫克口服氢化可的松或3×50毫克氢化可的松输液或i.m.1×40毫克和2×20毫克氢化可的松orally3×20毫克氢化可的松orally100 mg氢化可的松输液在inductionTaper术前dose2×50毫克氢化可的松输液或i.m. 6小时间隔注射。静脉注射;坜,肌内;不适用。*国家指南的本地翻译的剂量对于所有继续使用术前皮质类固醇的患者是相同的。地方指南于2013年8月实施,最近一次更新是在2019年2月。2017年1月至2018年6月期间,共有15246名患者在全身麻醉或脊髓麻醉下接受了选择性非心脏手术,其中390名患者有三期肾上腺功能不全的风险。患者的中位(IQR[范围])年龄为56岁(45-69[18-85]),女性178例(45%),计划行神经外科手术107例(27%)。在手术当天,390例患者中有32例(8%)按照指南补充了氢化可的松,188例(48%)因其他原因接受了另一种皮质类固醇,例如,地塞米松用于术后恶心或神经外科手术。其余170例(44%)患者均未接受补充。在147例(38%)接受低风险手术的患者中,26例(18%)根据指南接受了补充,38例(36%)因其他原因接受了皮质类固醇,其中36例(95%)接受了足够的等效剂量。在243例(62%)接受中/高危手术的患者中,6例(2%)根据指南接受了补充皮质类固醇,150例(62%)因其他原因接受了皮质类固醇。在这150例患者中,27例(18%)接受了足够的等效剂量。术后第一天,243例中/高危患者中有10例(4%)患者的围术期补充处方完全依从。总之,我院记录的围手术期皮质类固醇补充处方指南依从率为8%,与PREDs研究中发现的9%的依从率相似[10]。我们的研究早于麻醉师协会的指导方针,但结果表明,慢性使用者围手术期皮质类固醇补充仍然存在争议[10]。尽管已有60多年的建议,但这些指南是基于稀疏、低质量的证据,需要进一步审查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anaesthesia
Anaesthesia 医学-麻醉学
CiteScore
21.20
自引率
9.30%
发文量
300
审稿时长
6 months
期刊介绍: The official journal of the Association of Anaesthetists is Anaesthesia. It is a comprehensive international publication that covers a wide range of topics. The journal focuses on general and regional anaesthesia, as well as intensive care and pain therapy. It includes original articles that have undergone peer review, covering all aspects of these fields, including research on equipment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信